Qube Research & Technologies Ltd
Position in CNTA — Centessa Pharmaceuticals plc
CIK 1729829
LONDON, X0
Position in CNTA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
628,049
+65.8% QoQ
Ownership
0.406%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CNTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,042,063 across 169 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in CNTA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 628,049 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | — | 378,740 | Shares | Sole | 2026-02-17 | |
| 2025-06-30 | — | 307,880 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | — | 29,434 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | — | 107,058 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | — | 96,515 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | — | 3,523 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | — | 8,944 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | — | 1,311 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | — | 69 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||